The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

The triple therapy inhaler delivers 3 active ingredients: beclomethasone dipropionate, an inhaled corticosteroid, formoterol fumarate, a long-acting beta-agonist, and glycopyrrolate, an ...

The Food and Drug Administration (FDA) has extended the review for the Biologics License Application (BLA) for tividenofusp alfa for the treatment of Hunter syndrome, also known as ...

Evidence seen, however, for harmful effects from serious adverse events and several nonserious adverse events.

Improvements in cause-specific and overall survival seen for those residing in rural and high-poverty communities.

While personnel leading the CDC’s response to US measles outbreaks, suicide prevention and an overseas Ebola were spared, The Washington Post reports that fired officials included dozens responsible ...

HealthDay News — Among US military personnel and veterans reporting recent suicidal ideation and/or suicidal behaviors, brief cognitive behavioral therapy (BCBT) reduces suicide attempts, according to ...

Significantly increased adherence in both high- and low-risk children supports broader dissemination, authors say.

The blood-based biomarker test measures Tau protein phosphorylated at threonine 181 in human plasma (pTau181).

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

CTx-1301 is a novel proprietary formulation of dexmethylphenidate, a stimulant that increases norepinephrine and dopamine activity in the brain.

The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release injectable suspension) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance ...